Monday, September 15, 2014 8:19:58 AM
Milestone Scientific Receives CE Mark Approval for Intra-Articular Instrument
LIVINGSTON, NJ--(Marketwired - September 15, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its subsidiary, Milestone Medical, has received CE Mark regulatory approval to market and sell its intra-articular instrument in Europe.
Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "Receipt of regulatory approval in Europe for this instrument is validation of our technology and allows our subsidiary to move forward with its plans to commercialize the technology in Europe. Our subsidiary is now in the process of evaluating potential strategic partners to distribute its intra-articular instrument in Europe. We believe we are well positioned to enter this multi-billion dollar market since conventional injections are painful, a problem eliminated with our instrument, and not always efficacious, as doctors often fail to locate the intra-articular space or use inappropriate volumes of hyaluronic acid."
Milestone's injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other applications of controlling the pain that patients typically associate with injections.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
Source: Marketwired (September 15, 2014 - 7:30 AM EDT)
News by QuoteMedia
Recent MLSS News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 05:07:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 09:05:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 09:05:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 09:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 09:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 09:03:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 09:03:28 PM
- Milestone Scientific Provides Business Update and Reports Financial Results for the Second Quarter of 2024 • GlobeNewswire Inc. • 08/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:00:32 PM
- Milestone Scientific Schedules Second Quarter 2024 Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 08/12/2024 03:00:00 PM
- Milestone Scientific Announces Strategic Partnership with Axial Biologics to Distribute CompuFlo® in New Jersey, Texas, and Florida • GlobeNewswire Inc. • 08/07/2024 02:00:00 PM
- Milestone Scientific Secures Key Patent Approvals in the U.S. and Europe • GlobeNewswire Inc. • 07/30/2024 12:30:00 PM
- Milestone Scientific Announces Medicare Price Assignment for the CompuFlo® Epidural System in Texas, Pennsylvania, New Jersey, Maryland, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District of Columbia, and Delaware • GlobeNewswire Inc. • 07/23/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 07:47:33 PM
- Milestone Scientific Announces Favorable Medicare Pricing for its CompuFlo® Epidural System within First JMAC Region Covering Florida • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Milestone Scientific Receives Regulatory Approval to Market CompuFlo® Epidural System in Brazil • GlobeNewswire Inc. • 06/18/2024 03:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 06:11:22 PM
- Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2024 • GlobeNewswire Inc. • 05/16/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:01:31 PM
- Milestone Scientific Schedules First Quarter 2024 Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 05/13/2024 12:30:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023 • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 03/28/2024 03:45:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Omaha Pain Physicians • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® with Meridian Endo & Perio • GlobeNewswire Inc. • 02/28/2024 01:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM